Stemline Therapeutics, Inc. (NASDAQ:STML) has been given a consensus rating of “Buy” by the eight brokerages that are currently covering the firm, MarketBeat Ratings reports. One research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and six have given a buy recommendation to the company. The average 12-month target price among brokers that have updated their coverage on the stock in the last year is $32.25.
A number of equities analysts recently commented on STML shares. Jefferies Group LLC reissued a “buy” rating and issued a $16.00 price objective on shares of Stemline Therapeutics in a research note on Thursday, May 25th. Cowen and Company reaffirmed a “buy” rating on shares of Stemline Therapeutics in a research report on Wednesday, June 14th. Wedbush reaffirmed an “outperform” rating and set a $11.00 price target on shares of Stemline Therapeutics in a research report on Friday, March 17th. Zacks Investment Research raised Stemline Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, May 20th. Finally, HC Wainwright reaffirmed a “buy” rating on shares of Stemline Therapeutics in a research report on Monday, May 15th.
Several institutional investors have recently added to or reduced their stakes in STML. Ladenburg Thalmann Financial Services Inc. increased its position in Stemline Therapeutics by 810.6% in the fourth quarter. Ladenburg Thalmann Financial Services Inc. now owns 12,694 shares of the biopharmaceutical company’s stock valued at $136,000 after buying an additional 11,300 shares during the last quarter. AXA purchased a new position in Stemline Therapeutics during the first quarter valued at about $3,712,000. Renaissance Technologies LLC increased its position in Stemline Therapeutics by 7.9% in the fourth quarter. Renaissance Technologies LLC now owns 65,500 shares of the biopharmaceutical company’s stock valued at $701,000 after buying an additional 4,800 shares during the last quarter. Candriam Luxembourg S.C.A. purchased a new position in Stemline Therapeutics during the third quarter valued at about $2,783,000. Finally, State Street Corp increased its position in Stemline Therapeutics by 9.2% in the fourth quarter. State Street Corp now owns 251,804 shares of the biopharmaceutical company’s stock valued at $2,694,000 after buying an additional 21,296 shares during the last quarter. 54.18% of the stock is currently owned by hedge funds and other institutional investors.
Stemline Therapeutics (STML) traded down 1.20% on Friday, reaching $8.20. The company had a trading volume of 349,337 shares. The stock’s 50-day moving average is $8.08 and its 200-day moving average is $9.28. Stemline Therapeutics has a 52 week low of $5.50 and a 52 week high of $14.60. The company’s market capitalization is $191.68 million.
Stemline Therapeutics (NASDAQ:STML) last issued its quarterly earnings data on Wednesday, May 10th. The biopharmaceutical company reported ($0.67) EPS for the quarter, missing analysts’ consensus estimates of ($0.45) by $0.22. The business had revenue of $0.30 million during the quarter, compared to the consensus estimate of $0.30 million. Stemline Therapeutics had a negative return on equity of 60.51% and a negative net margin of 3,864.20%. Equities research analysts forecast that Stemline Therapeutics will post ($2.27) EPS for the current fiscal year.
About Stemline Therapeutics
Stemline Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing oncology therapeutics. The Company is developing approximately three clinical stage product candidates, including SL-401, SL-701 and SL-801. SL-401 is a targeted therapy directed to the interleukin-3 receptor (IL-3R) (CD123), present on a range of hematologic cancers.
Receive News & Ratings for Stemline Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stemline Therapeutics Inc. and related companies with our FREE daily email newsletter.